

RECEIVED
CENTRAL FAX CENTER
FEB 06 2006

PTO/SB/82 (09-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS	Application Number	10/549,460
	Filing Date	September 16, 2005
	First Named Inventor	Niklas Dahl
	Art Unit	1645
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	100852-1P US

I hereby revoke all previous powers of attorney given in the above-identified application.

☐ A Power of Attorney is submitted herewith.

OR

☒ I hereby appoint the practitioners associated with the Customer Number: 44992

☒ Please change the correspondence address for the above-identified application to:

☒ The address associated with
Customer Number:

44992

OR

☐ Firm or Individual Name AstraZeneca Pharmaceuticals LP


Address	Global Intellectual Property 35 Gatehouse Drive				
City	Waltham				
Country	USA	State	MA	Zip	02451
Telephone	(781) 839-4000			Fax	(781) 839-4121

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature			
Name	Tracey Bryant		
Date	18 January 2005	Telephone	+44 (0) 1625 513228

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☒ *Total of 1 forms are submitted.

RECEIVED
CENTRAL FAX CENTER

FEB 06 2006

PTO/SB/96 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Niklas Dahl

Application No.: 10/549,460

Filed: September 16, 2005

Entitled: GENES ASSOCIATED WITH OBESITY AND METHODS FOR USING THE SAME

AstraZeneca AB
(Name of Assignee)

, a Corporation
(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.

The extent (by percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Tracey Bryant
Signature

18 Jan 2005
Date

Tracey Bryant
Printed or Typed Name

Authorized Signer for Assignee
Title: Patent Director, Oncology & Infection

Telephone Number
+44 (0) 1625 513228

100852-1P US

ATTORNEY DOCKET NO.:

ASSIGNMENT

Now, therefore, for good and valuable consideration, receipt and sufficiency of which is hereby acknowledged, I/we

DAHL, Niklas of Uppsala University, Arosгатen 5, SE-752 36, Uppsala, Sweden

hereafter referred to as ASSIGNOR (S),

Hereby sell(s), assign(s) and transfer(s) to ASSIGNEE **AstraZeneca AB**, a company created and existing under the laws of Sweden, having its Head Office at SE-151 85 Södertälje, Sweden, and the successors, assigns and legal representatives of the ASSIGNEE, the entire right, title and interest for the United States and its territorial possessions, and in all foreign countries, in and to the inventions and any and all improvements thereon which are the subject of an application entitled:

GENES ASSOCIATED WITH OBESITY AND METHODS FOR USING THE SAME

And which is disclosed in:

- (a) ☐ U.S. patent application executed on even date herewith;
- (b) ☐ U.S. patent application executed on _____;
- (c) ☐ U.S. application no. _____ filed on _____;
- (d) ☒ International application no. PCT/GB2004/001124 filed on 16 March 2004 (16.03.2004).

And in and to the above application and any legal equivalent thereof in a foreign country, including the right to claim priority, and in and to any division, continuation or continuation-in-part, renewal or substitute thereof, and in and to all resulting Letters Patents or any reissue or reexamination thereof, to have and to hold the same to the full end of the term or terms for which any and all of said Letters Patent may be granted;

ASSIGNOR(S) authorize(s) and request(s) the issuing authority to issue any and all patents on said application or applications to said ASSIGNEE or its successors and assigns;


ASSIGNOR(S) hereby covenant(s) that ASSIGNOR(S) has/have the full power to make this assignment, and that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment; and

Without further payment or compensation by the ASSIGNEE or its successors and assigns, ASSIGNOR(S) further covenant(s) and agree(s) to communicate to said ASSIGNEE or its representatives, agents, its successors or assigns, any facts relating to said invention or inventions including evidence for purposes of interference or other administrative or legal proceedings whenever requested; to testify in any interference, legal or administrative proceedings, whenever requested; to execute and deliver, on request, all lawful papers required to make any of the foregoing provisions effective; and to do everything possible to aid said ASSIGNEE, its successors or assigns and nominees to secure, obtain and enforce proper patent protection for said invention or inventions in this or any foreign country.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

100852-1P US

IN WITNESS WHEREOF, I have hereunto set my hand and seal on the date below written.



DAHL, Niklas
Signature of Assignor

Sept. 5, 2005


Date of Assignor's Signature

WITNESSED BY:



Signature of Witness
Name of Witness
(Type or print clearly)

GISELA BARBANY



Signature of Witness
Name of Witness
(Type or print clearly)

Marie-Louise Borden-

Additional signature pages attached: ☐ Yes ☒ No